Research progress of NK cell immunodeficiency in immune escape of acute leukemia
Vol 5, Issue 2.1, 2021
VIEWS - 40 (Abstract) 30 (PDF)
Abstract
NK cell immunodeficiency has a variety of manifestations and complex mechanisms in the tumor. NK cell immune deficiency is closely related to immune escape of acute leukemia. This paper demonstrates the immunological escape mechanism of acute leukemia from NK cell immune deficiency manifestation and cause.
Keywords
Full Text:
PDFReferences
1. Huang X, Huang H. Hematology. 2nd ed. Beijing: People’s Medical Publishing House; 2004. p. 9–13.
2. Zhang Z, Hao Y, Zhao Y, et al. Hematology. 2nd ed. Beijing: People’s Medical Publishing House; 2015. p. 853–854.
3. Caligiuri MA. Human natural killer cells. Blood 2008; 112(3): 461–469.
4. Yu X, Gu G, Wang L, et al. Peripheral blood lymphocyte subsets of the absolute value of precise and quantitative analysis of immune function in acute leukemia. China Journal of Modern Medicine 2014; (17): 63–67.
5. Kong L, Ge J, Xia R. The significance of Treg and T lymphocyte subsets in acute myelocytic leukemia. Acta Universitatis Medicinalis Anhui 2015; (4): 512–515.
6. Sun H, Zhang L, Wang J. Clinical significance of diagnosis and treatment of Treg cells, NK cells and T lymphocyte subsets in patients with acute leukemia. Journal of Clinical Hematology 2016; (9): 741–743.
7. Ho X, Fook-Chong S, Linn YC. Natural killer cell receptor repertoire is comparable amongst newly diagnosed acute myeloid leukemia of different French-American British subtypes, risk categories and chemosensitivities. Leuk Lymphoma 2014; 55(2): 342–348.
8. Mundy-Bosse BL, Scoville SD, Chen L, et al. MicroRNA-29b mediates altered innate immune development in acute leukemia. The Journal of Clinical Investigation 2016; 126(12): 4404–4416.
9. Rouce RH, Shaim H, Sekine T, et al. The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemi. Leukemia 2016; 30(4): 800–811.
10. Rey J, Fauriat C, Kochbati E, et al. Kinetics of cytotoxic lymphocytes reconstitution after induction chemotherapy in elderly AML patients reveals progressive recovery of normal phenotypic and functional features in NK cells. Frontiers in Immunology 2017; 8(64): 1–12.
11. Stringaris K, Sekine T, Khoder A, et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica 2014; 99(5): 836–847.
12. Sanchez-Correa B, Gayoso I, Bergua JM, et al. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunology and Cell Biology 2012; 90(1): 109–115.
13. Sandoval-Borrego D, Moreno-Lafont MC, VazquezSanchez EA, et al. Overexpression of CD158 and NKG2A inhibitory receptors and underexpression of NKG2D and NKp46 activating receptors on NK cells in acute myeloid leukemia. Archives of Medical Research 2016; 47(1): 55–64.
14. Wu G, Yang Z, Wang Z, et al. Effect of CD158 receptor epitope blocking on killing activity of NK cells in acute myeloid leukemia. Journal of Guangdong Medical College 2013; (5): 509–512.
15. Gong F. Medical Immunology. 4th ed. Beijing: Science Press; 2014.
16. Chou J, Lin JH, Brenot A, et al. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nature Cell Biology 2013; 15(2): 201–213.
17. Yeh YY, Ozer HG, Lehman AM, et al. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood 2015; 125(21): 3297–3305.
18. Kirimura S, Kurata M, Nakagawa Y, et al. Role of microRNA-29b in myelodysplastic syndromes during transformation to overt leukaemia. Pathology 2016; 48(3): 233–241.
19. Damiani D, Tiribelli M, Raspadori D, et al. Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors. Oncotarget 2015; 6(30): 30212–30221.
20. Tiribelli M, Raspadori D, Geromin A, et al. High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients. Leukemia Research 2017; 58: 31–38.
21. Zhang X, Shen A, Guo R, et al. Expression characteristics of CD200 in acute myeloid leukemia and its clinical significance. Journal of Experimental Hematology 2014; (6): 1531–1534.
22. Tang M, Acheampong DO, Wang Y, et al. Tumoral NKG2D alters cell cycle of acute myeloid leukemic cells and reduces NK cell-mediated immune surveillance. Immunology Research 2016; 64(3): 754–764.
23. Hong CS, Muller L, Whiteside TL, et al. Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia. Frontiers in Immunology 2014; 5(160): 1–9.
24. Mao C, Mou X, Jiang Q, et al. Detection and analysis of human ULBP3 in different tumor cells and tumor tissues (in Chinese). Chinese Journal of Cellular and Molecular Immunology 2014; (12): 1307–1310.
25. Jiang Q, Mou X, Mao C, et al. The level of serum UL16 binding protein 3 (ULBP3) in patients with acute myeloid leukemia increased and inhibited the killing activity of NK cells (in Chinese). Chinese Journal of Cellular and Molecular Immunology 2015; (10): 1396–1398, 1403.
26. Folgiero V, Cifaldi L, Li PG, et al. TIM-3/Gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells. Journal of Hematology & Oncology 2015; 8(36): 1–5.
27. Ma J. Characteristics of Tim-3 expression on NK cells and its clinical significance in acute myeloid leukemia patients [Master’s thesis]. Suzhou: Soochow University; 2015.
28. Schmiedel BJ, Nuebling T, Steinbacher J, et al. Receptor activator for NF-κB ligand in acute myeloid leukemia: Expression, function, and modulation of NK cell immunosurveillance. Journal of Immunology 2013; 190(2): 821–831.
29. Lu Y, Liu J, Liu Y, et al. TLR4 plays a crucial role in MSC-induced inhibition of NK cell function. Biochemical and Biophysical Research Communications 2015; 464(2): 541–547.
30. Khaznadar Z, Henry G, Setterblad N, et al. Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse. European Journal of Immunology 2014; 44(10): 3068–3080.
31. Bellucci R, Martin A, Bommarito D, et al. Interferon-γ induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology 2015; 4(6): e1008824.
DOI: https://doi.org/10.24294/ti.v5.i2.1.1368
Refbacks
- There are currently no refbacks.
Copyright (c) 2021 Yuling Zhang, Zhong Yu, Hailiang Li
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This site is licensed under a Creative Commons Attribution 4.0 International License.